Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab to reduce need for surgery in severe bilateral nasal polyposis
2008-003772-21Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing Mepolizumab 750 mg with Placebo (2 arms). Primary endpoints: Reduced need for surgery at end of Part A and Change in nasal polyp size. Started Feb 2009; status: completed.
02
Drugs
mepolizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on 2008-003772-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003772-21.